Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May;55(5):105967.
doi: 10.1016/j.ijantimicag.2020.105967. Epub 2020 Apr 4.

Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19

D Praveen  1 , Ranadheer Chowdary Puvvada  2 , Vijey Aanandhi M  3
Affiliations

Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19

D Praveen et al. Int J Antimicrob Agents. 2020 May.

Abstract

The Wuhan outbreak of novel Corona virus infection has been the global focus since December 2019. This infection has become a global pandemic. It is highly important to understand the virology of the pathogen and to explore the therapeutic options for management of this pandemic. Drug repurposing strategies are being considered for management of COVID 19. Among the identified drugs, Baricitinib has become a keen interest for researchers because of its ability to inhibit the viral assembly by the prevention of Clarithrin associated endocytosis. We tried to explore the reasons on why Baricitinib is not an ideal option for COVID 19.

Keywords: Baricitinib; COVID 19; Novel Corona Virus; SARS-CoV-2.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Gruber CC, Steinkellner G.Wuhan coronavirus 2019-nCoV—what we can find out on a structural bioinformatics level. Jan23, 2020. https://innophore.com/2019-ncov/(accessed Feb 10, 2020).
    1. Lu R., Zhao X., Li J., Niu P., Yang B., Wu H. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565–574. - PMC - PubMed
    1. Richardson P., Griffin I., Tucker C., Smith D., Oechsle O., Phelan A. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020;395(10223):e30–e31. - PMC - PubMed
    1. Pu S.Y., Xiao F., Schor S., Bekerman E., Zanini F., Barouch-Bentov R. Feasibility and biological rationale of repurposing sunitinib and erlotinib for dengue treatment. Antiviral Res. 2018;155:67–75. - PMC - PubMed
    1. Sorrell F.J., Szklarz M., Abdul Areez K.R., Elkins J.M., Knapp S. Family-wide structural analysis of human numb-associated protein kinases. Structure. 2016;24:401–411. - PMC - PubMed